title: Drug delivery systems for the treatment of rheumatoid arthritis.
abstract: Rheumatoid arthritis (RA) is a severe immune-mediated disease characterized by chronically progressive inflammation and destruction of joints and associated structures. Significant advances in our understanding of its pathophysiology and early diagnosis have led to improved therapy and better outcome. Nevertheless, a number of details in the pathogenesis of RA are still unknown and thus the disease cannot be cured at present. Therefore, current therapy aims at accomplishing complete and long-lasting remission. However, this goal is only achieved in a small proportion of patients, and partial remission and frequent relapses are a common problem. A significant number of patients still do not respond at all to available treatments. In addition, all antirheumatic and immune-modulating drugs developed so far carry a considerable risk of adverse effects, some of which can be severe or even life threatening. This is due, at least in part, to a lack of specificity of most drugs for the target tissue, and to a high volume of distribution for systemic application, which, together with rapid clearance of most drugs, requires frequent application of high dosages. Targeted drug delivery and prolongation of bioavailability would alleviate this issue significantly. This article, therefore, reviews a selection of studies that report promising strategies for joint specific delivery of antiarthritic drugs.
authors.affiliation: Department of Internal Medicine and Rheumatology, Division of Rheumatology and Clinical Immunology, Justus-Liebig-University of Giessen, D-61231 Bad Nauheim, Germany.
authors.forename: Ingo H
authors.initials: IH
authors.lastname: Tarner
authors.forename: Ulf
authors.initials: U
authors.lastname: Müller-Ladner